Organ-on-a-chip technology MIMETAS specializes in organ-on-a-chip technology, offering innovative 3D human disease models that provide a physiologically relevant platform for drug development. Pharmaceutical companies seeking advanced in vitro models for drug screening and efficacy testing could benefit from partnerships with MIMETAS.

Recent collaborations MIMETAS has formed strategic partnerships with leading companies like Roche and Astellas, focusing on developing human disease models for specific therapeutic areas such as inflammatory bowel disease and immuno-oncological therapies. This demonstrates MIMETAS' credibility and expertise in catering to specialized drug discovery needs.

Award-winning innovation As the recipient of the Dutch Innovation Award 2022, MIMETAS has been recognized for its groundbreaking approach in disease modeling using organ-on-a-chip technology. Pharmaceutical companies looking for cutting-edge solutions and innovative platforms may find MIMETAS' offerings appealing.

Expanded product line With the launch of new organoid-based products like ASC-derived Colon1 and Kidney2 Organoid tubules, MIMETAS has expanded its OrganoReady® product line, providing additional tools for drug screening and personalized medicine applications. This diversification can attract companies seeking a comprehensive range of in vitro models.

Key leadership appointment MIMETAS appointed Dhaval Patel as Chair of the Board of Directors, bringing valuable expertise in the pharmaceutical and biotechnology industries. Companies interested in collaborations with MIMETAS could leverage Patel's experience to explore mutually beneficial business opportunities and strategic alliances.